生物制剂治疗白塞氏病葡萄膜炎的研究进展  

Research Progress on the Treatment of Behçet's Disease-associated Uveitis with Biologics

作　　者：牟庆帅 刘滨[1,2] 毕泗松 解孝锋 MOU Qingshuai;LIU Bin;BI Sisong;XIE Xiaofeng(Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250004,China)

机构地区：[1]山东中医药大学,济南250355 [2]山东中医药大学附属眼科医院,济南250004

出　　处：《中国中医眼科杂志》2025年第2期190-194,200,共6页China Journal of Chinese Ophthalmology

摘　　要：白塞氏病是一种累及多系统的慢性自身免疫性疾病,葡萄膜炎是其眼部并发症,可导致严重的视力损害。近年来,随着对白塞氏病葡萄膜炎(BU)发病机制的深入研究,抗肿瘤坏死因子-α(TNF-α)制剂在其治疗中取得了重要进展。本文对TNF-α抑制剂、干扰素-α(IFN-α)等生物制剂在BU治疗中的临床疗效、作用机制及安全性的研究进展进行综述,发现生物制剂能够显著降低BU患者的复发率,改善视力,且具有良好的耐受性。虽然生物制剂在BU治疗中的应用已经取得了一定的临床证据,但仍需进一步优化治疗方案以及预防感染。本研究可为BU的临床诊治提供参考。Behçet's disease(BD)is a chronic multisystem autoimmune disease,and uveitis is a common ocular complication that can lead to severe visual impairment.In recent years,significant progress has been made in the treatment of Behçet's disease-associated uveitis(BU)with the advent of anti-tumor necrosis factor-α(TNF-α)agents,driven by deeper insights into the pathogenesis of BU.This review summarizes the clinical efficacy,mechanisms of action,and safety of biologics such as TNF-αinhibitors and interferon-α(IFN-α)in the treatment of BU.Biologics have been shown to significantly reduce the recurrence rate of uveitis in BD patients,improve visual outcomes,and demonstrate good tolerability.Despite the promising clinical evidence supporting the use of biologics in BU treatment,further optimization of therapeutic regimens and strategies for infection prevention are needed.This study provides a reference for the clinical management of BU.

关 键 词：白塞氏病 葡萄膜炎 生物制剂 TNF-Α 

分 类 号：R773[医药卫生—眼科]